

cyclosporine (Sandoz Pharmaceutical Inc.); treated with the costimulation blockade plus rapamycin (Wyeth Research Institute, Princeton, NJ); treated with only cyclosporine; treated with only rapamycin; and untreated. A control group of three C3H/He mice received syngeneic transplants. The treatments were given as follows:

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (pages i - iii).

In the Claims:

Please amend Claims 11, 13 and 14 and add Claims 22-27. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - iii).

11. (Amended) A composition comprising rapamycin, or a biologically active derivative thereof, and at least one costimulation blockade agent, wherein the costimulation blockade agent comprises at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L and derivatives thereof.
13. (Amended) The composition of Claim 11 wherein the costimulation blockade agent comprises at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L and derivatives thereof.
14. (Amended) A kit comprising at least one costimulation blockade agent and rapamycin, wherein the costimulation blockade agent comprises at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L and derivatives thereof.

22.

(New) A composition comprising rapamycin, or a biologically active derivative thereof, and at least one costimulation blockade agent, wherein the costimulation blockade agent comprises at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L.

23. (New) The composition of Claim 22 further comprising fish oil.

24.

(New) A kit comprising rapamycin, or a biologically active derivative thereof, and at least one costimulation blockade agent comprising at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L.

25.

(New) A composition consisting essentially of rapamycin, or a biologically active derivative thereof, and at least one costimulation blockade agent comprising at least one agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L.

26.

(New) A composition consisting of:

- (a) rapamycin, or a biologically active derivative thereof;
- (b) at least one costimulation blockade agent selected from the group consisting of anti-CD40 antibodies, anti-CD40L antibodies, CD40-Ig, CD40L-Ig, and soluble extracellular domain proteins of CD40 and CD40L and derivatives thereof; and
- (c) at least one member selected from the group consisting of physiological carriers, vehicles, immunosuppressive agents, apoptosis agents, agonistic agents, antagonistic agents and fish oil.